Expression Profile of the Polycomb Group Protein Enhancer of Zeste Homologue 2 and its Prognostic Relevance in Renal Cell Carcinoma
Stefan Hinz(Charité - Universitätsmedizin Berlin), Carsten Kempkensteffen(Charité - Universitätsmedizin Berlin), Ahmed Magheli(Johns Hopkins University), Kurt Miller(Charité - Universitätsmedizin Berlin), Steffen Weikert(St. Hedwig-Krankenhaus), Rainer Engers(Heinrich Heine University Düsseldorf), Michèle J. Hoffmann(University Hospital of Bern)
Cited by 50
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k